Multicenter study: Effect of combined therapy using balloon-occluded arterial infusion of anticancer agent with concurrent radiation for elderly patients (or renal failure) with locally invasive bladder cancer

Multicenter study: Effect of combined therapy using balloon-occluded arterial infusion of anticancer agent with concurrent radiation for elderly patients (or renal failure) with locally invasive bladder cancer - Effect of BOAI of anticancer agent with concurrent radiation for locally invasive bladder cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002913

Enrollment

220

Registered

2009-12-17

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally invasive bladder cancer

Interventions

balloon-occluded-arterial-infusion (BOAI) of anticancer agent (cisplatin/gemcitabine), concomitant with radiation Total cystectomy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients were informed of the investigational nature of the study and provided written informed consent before study enrollment. (2) patients older than 75 years old, or with renal failure (3) Histological type should be urothelial cancer. (4) Stage T2 or T3 muscle-invasive bladder cancer without distant metastasis. (5) Eastern Cooperative Oncology Group (ECOG) performance status 0-2, (6) absolute neutrophil count (ANC) of 1,500/&#61549;L, platelets 100,000/&#61549;L, creatinine 1.0, bilirubin 3 times the institutional upper limit of the normal range, AST 4 times the institutional upper limit of the normal range,

Exclusion criteria

Exclusion criteria: Patients who : (1) had prior systemic therapy for bladder cancer (radiation or chemotherapy) (2) has serious complication (including severe DM) (3) other cancers. (4) are pregnant or wish to have baby (5) are unable to receive this treatment for some reason.

Design outcomes

Primary

Measure	Time frame
progression free survival	—

Secondary

Measure	Time frame
Over all survival Quality of life incidence rate of adverse event	—

Countries

Japan

Contacts

Public ContactHaruhito Azuma

Osaka Medical College Department of Urology

072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026